Citations

Clear

26 citation(s) found for "Thibault, P".

Abstract 16570: Benchmarking Risk-Adjusted Outcomes in Congenital Heart Surgery
Subramanyan, Ram Kumar, Thibault, Dylan, O’Brien, Sean M. , Shahian, David M. , Bacha, Emile , Badhwar, Vinay , Caldarone, C.A., Fernández, Félix G. , Pasquali, Sara K. , Rainey, Tabitha, Romano, Jennifer C., Shashidharan, Subhadra, Tweddell, James S., Mayer, John E. , Gaynor, J. William , Dearani, Joseph A. , Jacobs, Jeffrey P. , Overman, David M.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.16570 Get It

Background: Robust models exist to predict risk-adjusted mortality following congenital heart surgery. It is known that underlying diagnosis modifies predicted risk of operations, and institution-level outcomes vary based on their unique case mix. We therefore evaluated risk-adjusted outcomes for a subset of diagnosis-procedure (D-P) combinations within the Society of Thoracic Surgeons' (STS) congenital heart surgery database (CHSD). Methods: A clinician panel identified the most frequently encountered D-P combinations in CHSD between 07/2017 and 06/2021. Candidate modeling techniques were compared in a random 80% development cohort. Model performance was assessed using internal and cross-validation calibration, discrimination plots and optimism adjusted C-statistics. The final selected model was evaluated in the 20% validation sample. Results: The chosen subset of D-P combinations represented 45,384 of 87,589 (52%) unique episodes of surgical care in CHSD during this time-period. The development cohort (36,350 episodes) had 1.8% mortality (667 deaths). All candidate models had excellent discrimination with C-statistics ranging from 0.862 to 0.876. The model with the best combination of discrimination, calibration, and clinical face validity was a modified version of the current STS mortality risk model. This version included all current risk model variables with the addition of indicator variables for D-P combinations. In the 20% validation sample (9,034 episodes), this model was well calibrated (Figure) and had excellent discrimination (C = 0.879). Conclusion: We describe a cohort of D-P combinations widely encountered in the STS CHSD. Further, we refined the existing STS CHSD risk model for application to these D-P dyads to derive empirical risk-adjusted benchmark outcomes. This approach will benefit quality improvement efforts at an institutional level and may have implications for publicly reporting congenital heart surgery outcomes.
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study
Cohen, Mikaël , Thomel-Rocchi, Océane, Sıva, Aksel , Okuda, Darin T. , Karabudak, Rana , Terzi, Murat , Carra‐Dallière, Clarisse , Durand‐Dubief, Françoise , Thouvenot, Éric , Ciron, Jonathan , Bourre, Bertrand , Casez, Olivier , Moreau, Thibault, Neau, Jean‐Philippe, Pelletier, Daniel , Kantarci, Orhun H. , Tütüncü, Melih , Derache, Nathalie, Bensa, Caroline , Louapre, Céline , Benoit, Jeanne , Landes-Château, Cassandre , Carra Dallière, Clarisse , Thouvenot, Eric , Ciron, Jonathan , Lebrun‐Frénay, Christine , Siva, Aksel , Durand-Dubief, Françoise , Okuda, Darin T , Cohen, Mikaël , Efendi, Hüsnü , Zéphir, Hélène , Bourre, Bertrand , Casez, Olivier , Seze, Jerome De

Mayo Clinic

Multiple Sclerosis Journal | June 16, 2023 | Volume: 29 | Issue: 9 | Pages: 1099-1106

10.1177/13524585231179669 | PMID 37322880 Get It

Background: Vaccination in patients with multiple sclerosis (MS) treated with immunosuppressive drugs is highly recommended. Regarding COVID-19 vaccination, no specific concern has been raised. Objectives: We aimed to evaluate if COVID-19 vaccination or infection increased the risk of disease activity, either radiological or clinical, with conversion to MS in a cohort of people with a radiologically isolated syndrome (RIS). Methods: This multicentric observational study analyzed patients in the RIS Consortium cohort during the pandemic between January 2020 and December 2022. We compared the occurrence of disease activity in patients according to their vaccination status. The same analysis was conducted by comparing patients’ history of COVID-19 infection. Results: No difference was found concerning clinical conversion to MS in the vaccinated versus unvaccinated group (6.7% vs 8.5%, p > 0.9). The rate of disease activity was not statistically different (13.6% and 7.4%, respectively, p = 0.54). The clinical conversion rate to MS was not significantly different in patients with a documented COVID-19 infection versus non-infected patients. Conclusion: Our study suggests that COVID-19 infection or immunization in RIS individuals does not increase the risk of disease activity. Our results support that COVID-19 vaccination can be safely proposed and repeated for these subjects.
Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes
Chapoval, Andrei I. , Nelson, Heidi , Thibault, C

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 155 | Issue: 3 | Pages: 1296-1303

10.4049/jimmunol.155.3.1296 Get It

Abstract Bifunctional Abs (BFA) with specificity for the TCR/CD3 complex of T cells and tumor Ag can bridge T lymphocytes and tumor cells and, thereby, trigger activation events. The ability of intact and F(ab')2 anti-CD3 (500A2) x anti-p97 (96.5) BFA to induce activation of T lymphocytes in the presence of murine melanoma tumor cells (CL-62) expressing human melanoma-associated Ag (p97) was investigated in vitro and in vivo. Intact and F(ab')2 BFA induced significant proliferation of T lymphocytes in the presence of p97+ tumor cells. Incubation of splenocytes with intact or F(ab')2 BFA and p97+ tumor cells increased BFA-mediated cytotoxicity against relevant tumor cells. Intact BFA, in contrast to F(ab')2 BFA, induced some activation of T cells in vitro even in the absence of p97+ target cells. In nontumor-bearing mice, administration of F(ab')2 BFA, in contrast to intact BFA, did not increase cytotoxic activity of lymph node (LN) cells and splenocytes. However, when F(ab')2 BFA was administrated into CL-62-bearing mice, an increase of BFA-mediated cytotoxicity of tumor-infiltrating lymphocytes, but not splenocytes nor LN cells, was observed. Moreover, in D-galactosamine-sensitized mice, injection of intact BFA (1 microgram/mice) induced 100% lethality, whereas the same dose of F(ab')2 BFA was not toxic. These results demonstrate that F(ab')2 BFA can induce activation of cytotoxic lymphocytes only in the presence of relevant tumor cells, both in vitro and in vivo. That these activated lymphocytes can be redirected to lyse relevant tumor cells by the same BFA has important implications for the clinical application of BFA anti-tumor therapies.
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
Rollot, Fabien , Mondot, Lydiane, Louapre, Céline , Page, Emmanuelle Le , Durand‐Dubief, Françoise , Labauge, Pierre, Bensa, Caroline , Thouvenot, Éric , Ciron, Jonathan , Bourre, Bertrand , Cabre, Philippe, Casez, Olivier , Ruet, Aurélie , Mathey, Guillaume , Berger, Éric , Moreau, Thibault, Khedr, A. Al, Derache, Nathalie, Guennoc, Anne‐Marie, Créange, Alain , Neau, Jean‐Philippe, Tourbah, Ayman , Camdessanché, Jean‐Philippe , Maarouf, Adil , Callier, Céline, Kantarci, Orhun H. , Sıva, Aksel , Azevedo, Christina , Makhani, Naila , Pelletier, Daniel , Investigators, RISC, SFSEP, and OFSEP, Pelletier, Daniel, Azevedo, Christina, Radji, Fataï, Morel, Nathalie, Grosset-Jeannin, Deborah, Ungureanu, Aurelian , Boyer, L, Suchet, Laurent , Elias, Zyad, Brochet, Bruno, Defer, Gilles , Branger, Pierre , Clavelou, Pierre, Taithe, Frédéric, Alkhedr, Adullatif, Fromont, Agnès, Hautecoeur, Patrick, Androdias, G. , Ionescu, Iuliana, Pelletier, Jean , Audoin, Bertrand , Labauge, Pierre, Debouverie, Marc, Laplaud, David, Wiertlevski, Sandrine, Bresch, Saskia , Castelnovo, Giovanni, Papeix, Caroline , Lubetzki, Catherine , Stankoff, Bruno, Fontaine, Bertrand , Giannesini, C. , Heinzleff, Olivier, Bourre, Bertrand, Gout, Olivier , Guegen, Antoine, Leray, Emmanuelle , Guennoc, Anne Marie , Broucker, T. de , Sehaki, Sabrina, Devys-Meyer, Nathalie, Bereau, Mathieu, Cappe, Chrystelle, Kounkou, Katy-Kim, Dumont, Émilie , Lescieux, Edwige, Protin, Alexia, Kane, Maty Diop, Boucher, Julie, Petit, Julie, Kasonde, Irène Tabellah, Vilmarrest, Aymeric de, Nicol, Marie , Malbezin, Muriel, Olaiz, Javier, Rigaud-Bully, Claire, Vukusic, Irena, Debard, Nadine, Cotton, François, Abdelalli, Amalle, Lelio, Bernadette Di, Pinna, Frédéric , Guillemin, Francis, Ziegler, Amandine, Zehrouni, Karima, Hodel, Jérôme , Wahab, Abir , Zedet, Mickaël, Fagniez, Ombeline, Laage, Clémence, Pottier, Corinne , Slesari, Iuliana, Sampaio, Mathilde, Rabois, Emilie, Castex, Cédric , Hébant, Benjamin , Guillaume, Maxime , Vimont, Christine, Muraz, Romain, Port, Damien Le, Henry, Carole , Berthe, Carole, Freitas, Noellie, Visneux, Vincent, Forestier, M., Beltran, S. , Meunier, Géraldine, Servan, Jérôme, Pico, Fernando, Chatagner, Virginie, Siva, Aksel , Thouvenot, Eric , Ciron, Jonathan , Durand-Dubief, Françoise , Lebrun‐Frénay, Christine , Mondot, Lydiane , Zéphir, Hélène , Laplaud, David , Seze, Jerome De , Bourre, Bertrand , Casez, Olivier , Clavelou, Pierre , Vermersch, Patrick , Cohen, Mikaël , Okuda, Darin T. , Vukusic, Sandra , Investigators, RISC, SFSEP, and OFSEP, Azevedo, Christina, Morel, Nathalie, Boyer, Latine, Ouallet, Jean‐Christophe , Clavelou, Pierre, Outteryck, Olivier , Hautecoeur, Patrick, Ayrignac, Xavier , Carra‐Dallière, Clarisse , Labauge, Pierre, Laplaud, David, Maillart, Elisabeth , Bourre, Bertrand, Michel, Laure , Magy, Laurent , Collongues, Nicolas , Biotti, Damien , Béreau, Matthieu , Casey, Romain , Muraz, Romain, Forestier, Melanie

Mayo Clinic

JAMA Network Open | October 17, 2021 | Volume: 4 | Issue: 10 | Pages: e2128271

10.1001/jamanetworkopen.2021.28271 | PMID 34633424 Get It

Updating an Empirically Based Tool for Analyzing Congenital Heart Surgery Mortality
Jacobs, Marshall L., Jacobs, Jeffrey P. , Thibault, Dylan, Hill, Kevin D. , Anderson, Brett R. , Karamlou, Tara , Kumar, S. Ram , Mayer, John E. , Mery, Carlos M. , Nathan, Meena , Overman, David M. , Pasquali, Sara K. , Shahian, David M. , O’Brien, Sean M. , Kumar, S Ram , Jacobs, Jeffery P , Eghtesady, Pirooz , Louis, James D. St.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | March 8, 2021 | Volume: 12 | Issue: 2 | Pages: 246-281

10.1177/2150135121991528 | PMID 33683997 Get It

Objectives: STAT Mortality Categories (developed 2009) stratify congenital heart surgery procedures into groups of increasing mortality risk to characterize case mix of congenital heart surgery providers. This update of the STAT Mortality Score and Categories is empirically based for all procedures and reflects contemporary outcomes. Methods: Cardiovascular surgical operations in the Society of Thoracic Surgeons Congenital Heart Surgery Database (January 1, 2010 – June 30, 2017) were analyzed. In this STAT 2020 Update of the STAT Mortality Score and Categories, the risk associated with a specific combination of procedures was estimated under the assumption that risk is determined by the highest risk individual component procedure. Operations composed of multiple component procedures were eligible for unique STAT Scores when the statistically estimated mortality risk differed from that of the highest risk component procedure. Bayesian modeling accounted for small denominators. Risk estimates were rescaled to STAT 2020 Scores between 0.1 and 5.0. STAT 2020 Category assignment was designed to minimize within-category variation and maximize between-category variation. Results: Among 161,351 operations at 110 centers (19,090 distinct procedure combinations), 235 types of single or multiple component operations received unique STAT 2020 Scores. Assignment to Categories resulted in the following distribution: STAT 2020 Category 1 includes 59 procedure codes with model-based estimated mortality 0.2% to 1.3%; Category 2 includes 73 procedure codes with mortality estimates 1.4% to 2.9%; Category 3 includes 46 procedure codes with mortality estimates 3.0% to 6.8%; Category 4 includes 37 procedure codes with mortality estimates 6.9% to 13.0%; and Category 5 includes 17 procedure codes with mortality estimates 13.5% to 38.7%. The number of procedure codes with empirically derived Scores has grown by 58% (235 in STAT 2020 vs 148 in STAT 2009). Of the 148 procedure codes with empirically derived Scores in 2009, approximately one-half have changed STAT Category relative to 2009 metrics. The New STAT 2020 Scores and Categories demonstrated good discrimination for predicting mortality in an independent validation sample (July 1, 2017-June 30, 2019; sample size 46,933 operations at 108 centers) with C-statistic = 0.791 for STAT 2020 Score and 0.779 for STAT 2020 Category. Conclusions: The updated STAT metrics reflect contemporary practice and outcomes. New empirically based STAT 2020 Scores and Category designations are assigned to a larger set of procedure codes, while accounting for risk associated with multiple component operations. Updating STAT metrics based on contemporary outcomes facilitates accurate assessment of case mix.
Sensory Innervation of the Hip Joint and Referred Pain: A Systematic Review of the Literature
Dalmas, Yoann , Tibbo, Meagan E. , Robert, Suzanne, Durant, Thibault, Caste, Thomas, Vialla, Tristan , Tiercelin, Joris, Gracia, Gauthier, Chaynes, Patrick, Laumonerie, Pierre , Robert, Suzanne

Mayo Clinic

Pain Medicine | February 6, 2021 | Volume: 22 | Issue: 5 | Pages: 1149-1157

10.1093/pm/pnab061 | PMID 33565587 Get It

Abstract Objectives The aim of this literature review was to establish consensus with respect to the anatomic features of the articular branches innervating the hip joint and the distribution of sensory receptors within its capsule. Methods Five electronic databases were queried, with the search encompassing articles published between January 1945 and June 2019. Twenty-one original articles providing a detailed description of sensory receptors around the hip joint capsule (n=13) and its articular branches (n=8) were reviewed. Results The superior portions of the anterior capsule and the labrum were found to be the area of densest nociceptive innervation. Similar to the distribution of nociceptors, mechanoreceptor density was found to be higher anteriorly than posteriorly. Hip joint capsular innervation was found to consistently involve the femoral and obturator nerves, which supply the anterior capsule, and the nerve to the quadratus femoris, which supplies the posterior capsule. The femoral, obturator, and superior gluteal nerves supply articular branches to the most nociceptor-rich region of the hip capsule. Conclusions The femoral and obturator nerves and the nerve to the quadratus femoris were found to consistently supply articular branches to both the anterior and posterior capsule of the hip joint. The anterior capsule, primarily supplied by the femoral and obturator nerves, and the superior labrum appear to be the primary pain generators of the hip joint, given their higher density of nociceptors and mechanoreceptors. Level of Evidence Anatomy study, literature review.
Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement
Simonato, Matheus , Ribeiro, Henrique Barbosa , Webb, John G. , Backer, Ole De , Villablanca, Pedro, Rihal, Charanjit S. , Eleid, Mackram F. , Kempfert, Jörg , Unbehaun, Axel , Erlebach, Magdalena , Casselman, Filip , Saia, Francesco , Ubben, Timm , Meincke, Felix , Napodano, Massimo, Codner, Pablo , Schöfer, Joachim, Pelletier, Marc , Cheung, Anson , Shuvy, Mony , Palma, José Honório , Duncan, Alison , Sinning, Jan-Malte, Arbel, Yaron , Weger, Arend de , Eltchaninoff, Hélène, Hemery, Thibault, Tchétché, Didier , Dumonteil, Nicolas, Rodés‐Cabau, Josep , Kim, Won-Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben‐Yehuda, Ori , Barbanti, Marco , Fiorina, Claudia , Thukkani, Arun K., Jones, Noah, Presbitero, Patrizia , Petronio, Anna Sonia , Champagnac, Didier , Rudolph, Tanja K. , Iadanza, Alessandro , Nombela‐Franco, Luis , Bonaros, Nikolaos , Kass, Malek , Amabile, Nicolas , Messina, Antonio , Andreas, Martin , Welsh, Robert C. , Schoels, Wolfgang , Hellig, Farrel, Windecker, Stephan , Stortecky, Stefan , Maisano, Francesco , Stone, Gregg W. , Dvir, Danny , Rihal, Charanjit, Eleid, Mackram, Nombela-Franco, Luis , Windecker, Stephan , Maisano, Francesco , De Backer, Ole , Whisenant, Brian K. , Kornowski, Ran , Guerrero, Mayra , Wijeysundera, Harindra C. , Søndergaard, Lars , Rihal, Charanjit S. , Adam, Matti , Montorfano, Matteo , Ancona, Marco , Gaia, Diego Felipe , Hildick-Smith, David , Veulemans, Verena , Sinning, Jan‐Malte, Testa, Luca , Landes, Uri , Kim, Won-Keun, Teles, Rui Campante , Mackensen, G. Burkhard , Allali, Abdelhakim , Bleiziffer, Sabine , Salizzoni, Stefano , Agrifoglio, Marco , Bruschi, Giuseppe , Chhatriwalla, Adnan K , Hirji, Sameer

Mayo Clinic

Circulation | September 25, 2020 | Volume: 143 | Issue: 2 | Pages: 104-116

10.1161/circulationaha.120.049088 | PMID 32975133 Get It

Background: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. Methods: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mm Hg and significant residual mitral regurgitation (MR) as ≥ moderate. Results: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76–996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510–1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR ( P <0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mm Hg (≥5 mm Hg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients ( P =0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P <0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P =0.02). The rates of Mitral Valve Academic Research Consortium–defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P =0.01), mostly related to having postprocedural mean gradient ≥5 mm Hg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74–12.56; P =0.002) and significant residual MR (subhazard ratio, 7.88; 95% CI, 2.88–21.53; P <0.001) were both independently associated with repeat mitral valve replacement. Conclusions: Significant residual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated with a need for repeat valve replacement. Strategies to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.
Triage of patients with venous and lymphatic diseases during the COVID-19 pandemic – The Venous and Lymphatic Triage and Acuity Scale (VELTAS)
Parsi, Kurosh , Rij, André M. van , Meissner, Mark H. , Gloviczki, Péter , Benson, Stephen, Bottini, Oscar, Canata, Victor , Dinnen, Paul, Gasparis, Antonios, Gianesini, Sergio , Lal, Brajesh K. , Kabnick, Lowell S , Marston, William A. , Granados, Alberto Martinez, Morrison, Nick , Paraskevas, P, Patel, Malay , Roberts, Stefania , Komlos, Pedro, Varghese, Roy , Welch, Harold J. , Wittens, Cees H.A. , Parsi, Kurosh , Davies, Alun H. , Maeseneer, Marianne De , Huber, David, Jenkins, David, Lim, Adrian, Nicolaides, Andrew , Rogan, Christopher , Schul, Marlin W. , Stirling, Andy , Thibault, Simon , Gloviczki, Péter

Mayo Clinic

Phlebology: The Journal of Venous Disease | July 8, 2020 | Volume: 35 | Issue: 8 | Pages: 550-555

10.1177/0268355520930884 | PMID 32639862 Get It

The coronavirus disease 2019 (COVID-19) global pandemic has resulted in diversion of healthcare resources to the management of patients infected with SARS-CoV-2 virus. Elective interventions and surgical procedures in most countries have been postponed and operating room resources have been diverted to manage the pandemic. The Venous and Lymphatic Triage and Acuity Scale was developed to provide an international standard to rationalise and harmonise the management of patients with venous and lymphatic disorders or vascular anomalies. Triage urgency was determined based on clinical assessment of urgency with which a patient would require medical treatment or surgical intervention. Clinical conditions were classified into six categories of: (1) venous thromboembolism (VTE), (2) chronic venous disease, (3) vascular anomalies, (4) venous trauma, (5) venous compression and (6) lymphatic disease. Triage urgency was categorised into four groups and individual conditions were allocated to each class of triage. These included (1) medical emergencies (requiring immediate attendance), example massive pulmonary embolism; (2) urgent (to be seen as soon as possible), example deep vein thrombosis; (3) semi-urgent (to be attended to within 30–90 days), example highly symptomatic chronic venous disease, and (4) discretionary/non-urgent- (to be seen within 6–12 months), example chronic lymphoedema. Venous and Lymphatic Triage and Acuity Scale aims to standardise the triage of patients with venous and lymphatic disease or vascular anomalies by providing an international consensus-based classification of clinical categories and triage urgency. The scale may be used during pandemics such as the current COVID-19 crisis but may also be used as a general framework to classify urgency of the listed conditions.
Redesigning the Learning Environment to Promote Learner Well-Being and Professional Development
Lipscomb, Wanda, Thibault, George E., Dyrbye, Liselotte N.

Mayo Clinic

Academic Medicine | December 2, 2019 | Volume: 95 | Issue: 5 | Pages: 674-678

10.1097/acm.0000000000003094 | PMID 31789840 Get It

There is a high prevalence of burnout and depression among medical students and residents (or learners), which can negatively impact them personally, their professional development, and the patients to whom they provide care. Educators have a responsibility for the system-level factors that influence learners’ well-being. In this Invited Commentary, the authors outline strategies institutions and affiliated training sites responsible for educating learners can take to pursue the recommended goal related to learners, their well-being, and the learning environment in the National Academies of Sciences, Engineering, and Medicine consensus study report, Taking Action Against Clinician Burnout: A Systems Approach to Professional Well-Being .